Biotech · Private company
Apexigen America, Inc.
Track this companyFree. Adds Apexigen America, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- APX005MPhase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- APX005MPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Radiation TherapyPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Surgical resection of tumorPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)PHASE1 · COMPLETED · started Sep 14, 2020ClinicalTrials.gov NCT04495257 · fetched Nov 12, 2026
- INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal CancerPHASE2 · COMPLETED · started Apr 24, 2020ClinicalTrials.gov NCT04130854 · fetched Nov 12, 2026
- APX005M and Doxorubicin in Advanced SarcomaPHASE2 · COMPLETED · started Mar 20, 2019ClinicalTrials.gov NCT03719430 · fetched Nov 12, 2026
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaPHASE1 · TERMINATED · started Oct 8, 2018ClinicalTrials.gov NCT03597282 · fetched Nov 12, 2026
- APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaPHASE1 · COMPLETED · started Jun 9, 2018ClinicalTrials.gov NCT03502330 · fetched Nov 12, 2026
- APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction CancersPHASE2 · COMPLETED · started Oct 6, 2017ClinicalTrials.gov NCT03165994 · fetched Nov 12, 2026
- Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaPHASE1_PHASE2 · COMPLETED · started Jul 21, 2017ClinicalTrials.gov NCT03214250 · fetched Nov 12, 2026
- CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabPHASE1_PHASE2 · COMPLETED · started Jul 10, 2017ClinicalTrials.gov NCT03123783 · fetched Nov 12, 2026
- APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaPHASE1_PHASE2 · TERMINATED · started Jun 2, 2017ClinicalTrials.gov NCT02706353 · fetched Nov 12, 2026
- Study of the CD40 Agonistic Monoclonal Antibody APX005MPHASE1 · COMPLETED · started May 1, 2015ClinicalTrials.gov NCT02482168 · fetched Nov 12, 2026